IFM Investors Pty Ltd Reduces Stock Position in Danaher Corporation $DHR

Key Points

• IFM Investors Pty Ltd reduced its stake in Danaher Corporation by 1.6%, selling 2,076 shares and holding a total of 130,332 shares valued at approximately $26.7 million.
• Several institutional investors significantly increased their positions in Danaher, including GAMMA Investing LLC, which raised its stake by over 24,958% to nearly 1.9 million shares.
• Analysts have a consensus rating of "Moderate Buy" on Danaher, with an average target price of $246.35, reflecting positive sentiment among 17 research analysts.

IFM Investors Pty Ltd lowered its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 1.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 130,332 shares of the conglomerate's stock after selling 2,076 shares during the period. IFM Investors Pty Ltd's holdings in Danaher were worth $26,718,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Hills Bank & Trust Co raised its position in shares of Danaher by 0.3% in the first quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after purchasing an additional 53 shares during the period. Sageworth Trust Co raised its position in shares of Danaher by 2.3% in the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after purchasing an additional 54 shares during the period. 1834 Investment Advisors Co. raised its position in shares of Danaher by 3.3% in the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock valued at $342,000 after purchasing an additional 54 shares during the period. Rakuten Securities Inc. raised its position in shares of Danaher by 33.3% in the first quarter. Rakuten Securities Inc. now owns 224 shares of the conglomerate's stock valued at $46,000 after purchasing an additional 56 shares during the period. Finally, Kingswood Wealth Advisors LLC raised its position in shares of Danaher by 1.6% in the first quarter. Kingswood Wealth Advisors LLC now owns 3,466 shares of the conglomerate's stock valued at $710,000 after purchasing an additional 56 shares during the period. Institutional investors own 79.05% of the company's stock.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 11.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on DHR shares. Barclays reaffirmed an "overweight" rating and set a $225.00 target price (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Robert W. Baird upped their target price on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. UBS Group decreased their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a report on Wednesday, July 23rd. Finally, Evercore ISI decreased their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $246.35.

Danaher Price Performance

DHR stock traded down $2.02 during midday trading on Monday, reaching $188.03. The company had a trading volume of 2,210,543 shares, compared to its average volume of 4,128,080. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The company has a market capitalization of $134.64 billion, a P/E ratio of 40.02, a P/E/G ratio of 2.65 and a beta of 0.75. The firm has a 50-day moving average price of $201.21 and a 200-day moving average price of $198.78.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter in the previous year, the company earned $1.72 EPS. The business's quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio is 27.23%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.